Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (AVDL) Revenue
Annual & quarterly revenue history · segment & region breakdown
AVDL · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAvadel Pharmaceuticals plc trailing twelve-month (TTM) revenue is $0.25B, an increase of 504.79% year-over-year from $0.17B in FY2024.
Revenue trend
2024 – 2005 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.17B | +$0.14B | +504.79% |
| 2023-12-31 | $0.03B | +$0.03B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | -$0.02B | -100.00% |
| 2020-12-31 | $0.02B | -$0.04B | -62.28% |
| 2019-12-31 | $0.06B | -$0.04B | -42.66% |
| 2018-12-31 | $0.10B | -$0.07B | -40.22% |
| 2017-12-31 | $0.17B | +$0.02B | +14.97% |
| 2016-12-31 | $0.15B | -$0.02B | -13.26% |
| 2015-12-31 | $0.17B | +$0.16B | +1072.31% |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare AVDL revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Avadel Pharmaceuticals plc receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Avadel Pharmaceuticals plc reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Avadel Pharmaceuticals plc's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AVDL revenue · 4 questionsAVDL's trailing twelve-month (TTM) revenue is $0.25B. That is an increase of 504.79% year-over-year from $0.17B in FY2024.
▸ Source: FMP · Avadel Pharmaceuticals plc SEC filings · GAAP · Avadel Pharmaceuticals plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026